TY - JOUR
T1 - Adopting advance directives reinforces patient participation in end-of-life care discussion
AU - Hong, Ji Hyung
AU - Kwon, Jung Hye
AU - Kim, Il Kyu
AU - Ko, Jin Hee
AU - Kang, Yi Jin
AU - Kim, Hoon Kyo
N1 - Publisher Copyright:
© 2016 by the Korean Cancer Association.
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Purpose In Korea, most terminal cancer patients have still not been included in end-of-life (EOL) discussions. The purpose of this study was to evaluate the proportion of patients participating in EOL discussions after adopting advance directives. Materials and Methods Medical records of 106 hospice patients between July 2012 and February 2013 were reviewed retrospectively. The proportion of patient participation in EOL discussions, barriers, and favorable factors for completion of advance directives, as well as outcomes of advance directives were evaluated. Results Patient participation in EOL discussion had increased from 16/53 (30%) to 27/53 (51%) since adopting advance directives (p < 0.001). Median time between completion of an advance directive and death increased from 8 days (range, 0 to 22 days) to 14.5 days (range, 0 to 47 days). Patients' poor condition after late referral was the main barrier to missing EOL discussions; however, family members' concerns about patient's distress was also a main reason for excluding the patient from EOL discussions. In univariate analysis, patient age, education status, and time from diagnosis to completion of an advance directive influenced advance directive completion favorably. Following multivariate analysis, higher education and periods of more than 2 years from diagnosis to completion of an advance directive remained favorable (odds ratio [OR], 9.586, p=0.024 and OR, 70.312; p=0.002). Preferences of all patients regarding cardiopulmonary resuscitation or hemodialysis were carried out by physicians. Orders for nutrition and palliative sedation showed discordance, with concordance rates of 74.2% and 51.6%, respectively. Conclusion Our results suggested that the use of advance directive promote patient participation in EOL discussion.
AB - Purpose In Korea, most terminal cancer patients have still not been included in end-of-life (EOL) discussions. The purpose of this study was to evaluate the proportion of patients participating in EOL discussions after adopting advance directives. Materials and Methods Medical records of 106 hospice patients between July 2012 and February 2013 were reviewed retrospectively. The proportion of patient participation in EOL discussions, barriers, and favorable factors for completion of advance directives, as well as outcomes of advance directives were evaluated. Results Patient participation in EOL discussion had increased from 16/53 (30%) to 27/53 (51%) since adopting advance directives (p < 0.001). Median time between completion of an advance directive and death increased from 8 days (range, 0 to 22 days) to 14.5 days (range, 0 to 47 days). Patients' poor condition after late referral was the main barrier to missing EOL discussions; however, family members' concerns about patient's distress was also a main reason for excluding the patient from EOL discussions. In univariate analysis, patient age, education status, and time from diagnosis to completion of an advance directive influenced advance directive completion favorably. Following multivariate analysis, higher education and periods of more than 2 years from diagnosis to completion of an advance directive remained favorable (odds ratio [OR], 9.586, p=0.024 and OR, 70.312; p=0.002). Preferences of all patients regarding cardiopulmonary resuscitation or hemodialysis were carried out by physicians. Orders for nutrition and palliative sedation showed discordance, with concordance rates of 74.2% and 51.6%, respectively. Conclusion Our results suggested that the use of advance directive promote patient participation in EOL discussion.
KW - Advance directives
KW - Decision making
KW - Personal autonomy
UR - http://www.scopus.com/inward/record.url?scp=84963787605&partnerID=8YFLogxK
U2 - 10.4143/crt.2015.281
DO - 10.4143/crt.2015.281
M3 - Article
C2 - 26511808
AN - SCOPUS:84963787605
SN - 1598-2998
VL - 48
SP - 753
EP - 758
JO - Cancer Research and Treatment
JF - Cancer Research and Treatment
IS - 2
ER -